Sarepta Therapeutics, Inc. (SRPT)
17.00
-0.55
(-3.13%)
USD |
NASDAQ |
May 18, 16:00
17.00
0.00 (0.00%)
After-Hours: 20:00
Sarepta Therapeutics Research and Development Expense (Quarterly) : 153.96M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| PTC Therapeutics, Inc. | 100.87M |
| Keros Therapeutics, Inc. | 16.10M |
| REGENXBIO, Inc. | 53.48M |
| Alnylam Pharmaceuticals, Inc. | 364.87M |
| Cytokinetics, Inc. | 92.15M |